Open an account

TCGX Acquisition

TCGX · NASDAQ

$10.10+$0.07 (+0.70%)TodayMarket closed ·
Prev close $10.03

About TCGX

TCGX Acquisition Corp is a US-based company operating in industry. The company is headquartered in Palo Alto, California. The company went IPO on 2026-08-05. TCGX Acquisition Corp. is a blank check company. The firm is formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. The firm has not selected any business combination target and has not, nor has anyone on its behalf, initiated any substantive discussions, directly or indirectly, with any business combination target. The company may pursue an initial business combination in any business or industry. The firm is not engaged in any business operations and has not generated any revenue.

Employees
0
Headquarters
Palo Alto, California
Listed
Aug 5, 2026
Sector
N/A
Industry
N/A

TCGX key statistics

Market cap
114.17M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
196.67K
Volume
178.57K
Open price
$10.02
High today
$10.15
Low today
$10.02
52 Week high
$18.91
52 Week low
$9.90

TCGX Acquisition (TCGX) at a glance

As of Oct 23, 2026, TCGX Acquisition (TCGX) shares are priced at $10.10, giving the company a market cap of 114.17M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $10.02 and $10.15. The current price is 0.8% above the day's low and 0.5% below its high.

Volume so far is 178.57K shares, in line with the average of 196.67K shares a day.

Over the past year TCGX Acquisition has ranged from $9.90 to $18.91, and now sits 2% of the way up that range.

TCGX news

  • Press releaseBusiness Wire

    TriGemX Bio and TCGX Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Company to Develop Elismetrep, a Potential First-in-Class Treatment for Migraine

  • Press releaseBusiness Wire

    TriGemX Bio and TCGX Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Company to Develop Elismetrep, A Potential First-in-Class Treatment for Migraine

  • Press releaseBusiness Wire

    TCGX Acquisition Corp. Announces Completion of its Initial Public Offering

  • Press releaseBusiness Wire

    TCGX Acquisition Corp. Announces Pricing of $75,000,000 Initial Public Offering

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.